RLS-0071 is under clinical development by ReAlta Life Sciences and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RLS-0071’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RLS-0071 overview

RLS-0071 (PIC1-01) is under development for the treatment of graft versus host disease (GvHD), neonatal hypoxic-ischemic encephalopathy (HIE), systemic lupus erythematosus (SLE), acute hemolysis (acute hemolytic transfusion reactions), infectious diseases caused by Pseudomonas aeruginosa, influenza virus infections, respiratory syncytial virus infections and severe asthma, acute lung injury due to COVID-19 Gardnerella vaginalis, Prevotella bivia and acute exacerbations of chronic obstructive pulmonary disease (AE-COPD. The drug candidate consists of a 15 amino acid peptide conjugated with PEG and acts by targeting the complement C1q. It is administered through intravenous route.
The therapeutic candidate was under development for the treatment of systemic lupus erythematosus (SLE), Staphylococcus aureus, Klebsiella pneumoniae, Neisseria meningitidis and Neisseria gonorrhoeae.

ReAlta Life Sciences overview

ReAlta Life Sciences is a clinical stage biotech company. The company discovers, develops, novel therapeutics with a dual targeting approach designed to rebalance complement and inflammatory processes through its PIC1 technology platform. Its first target is complemented pathway and second target is inhibiting innate inflammatory processes. The company’s product pipeline includes neurology, pulmonology, hematology for the treatment of hypoxic ischemic encephalopathy (HIE), acute lung injury and severe asthma, acute pulmonary exacerbations, chronic obstructive pulmonary disease (COPD), and platelet refractoriness. It also provides research and development services. ReAlta Life Sciences is headquartered in Norfolk, Virginia, the US.

For a complete picture of RLS-0071’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.